2022 Southern Medical Research Conference
What Is Triple X Syndrome?
Medically reviewed by Daniel Combs, MD
Triple X syndrome (trisomy X or 47, XXX) is a genetic condition that occurs when a female is born with three X chromosomes in all or most of her cells rather than the usual two. Signs and symptoms of triple X syndrome vary widely. Some people may have no signs or symptoms, while others may experience developmental, psychological, and medical symptoms.
Triple X syndrome was first described in 1959 by Scottish geneticist Patricia Jacobs, who discovered a patient with premature ovarian failure had three X chromosomes. Since then, research shows that approximately 1 in 1,000 females are born with triple X syndrome, though only 10% are diagnosed in their lifetime.
This article describes the symptoms associated with triple X syndrome, how it is diagnosed, and the support and treatment options for people with it.
Triple X Syndrome SymptomsSigns and symptoms of triple X syndrome vary widely—some people may have no symptoms or may only be mildly affected, while others may have more noticeable symptoms.
Though not everyone with triple X syndrome has apparent physical features associated with the condition, many have some or all of the following:
Tall stature and long limbs (arms and legs)
Flat feet
Curved pinky finger (clinodactyly)
The skin of the upper eyelid covering the inner corner of the eye (epicanthal eyelid)
Wide-spaced eyes (hypertelorism)
Low muscle tone (hypotonia)
Many people with triple X syndrome experience a range of developmental, physical, and psychological symptoms, including:
Most people with triple X syndrome experience normal sexual development and fertility. Still, some have abnormal ovarian development (dysgenesis), menstrual irregularities, delayed or early onset puberty, or primary ovarian failure.
Story continues
What Causes Triple X Syndrome?Triple X syndrome is a genetic disorder not usually inherited from a biological parent. It occurs as a random chromosomal error during the formation of reproductive cells (egg and sperm) in one of the parents or early in an embryo's development.
Typically, people have 46 chromosomes in each of their body's cells. Two of these chromosomes—X and Y—are sex chromosomes that determine whether a person is born male or female. Females are usually born with XX sex chromosomes, but females born with trisomy X will have an extra copy of the X chromosome in each of their cells.
While most people born with triple X have an extra copy of the X chromosome in all of their body's cells, some only have an extra X in some of their cells. This is known as 46, XX/47, XXX mosaicism, associated with milder symptoms and fewer developmental and learning delays.
Triple X syndrome cannot be prevented and does not occur due to something a parent did or didn't do before conception or during pregnancy. Some research suggests women of advanced maternal age (35 or older) are more likely to give birth to a child with triple X syndrome than younger people. However, other studies show that advanced maternal age does not significantly increase the risk.
How Is Triple X Syndrome Diagnosed?Most babies born with triple X syndrome do not have any obvious physical signs or symptoms at birth. The condition is often undetected until early childhood, when parents express concern to a healthcare provider about their daughter's developmental or language delays.
If a healthcare provider suspects triple X syndrome, they will take a blood sample and send it to the lab for an analysis of the chromosomes, which can detect extra X chromosomes in the cells.
In recent years, routine prenatal testing has increasingly detected triple X syndrome during pregnancy. Prenatal screening tests, such as noninvasive prenatal testing (NIPT) or chorionic villus sampling (CVS), can check for genetic disorders like triple X syndrome in fetuses. If NIPT or CVS results indicate that the fetus may have triple X syndrome, an amniocentesis (a procedure to test amniotic fluid) can be performed to confirm the diagnosis.
Sometimes, a triple X syndrome diagnosis may be incidental and given when genetic testing is performed for a different medical condition. Because it often causes mild symptoms (if any), experts believe that only 10% of people with triple X syndrome get diagnosed.
Treatment for Triple X SyndromeThere is no cure for triple X syndrome, but many treatments and interventions can help manage symptoms and improve quality of life. Treatment for triple X syndrome depends on individual symptoms and the age of diagnosis.
Triple X syndrome treatments can include:
Early intervention services: Children with triple X syndrome may benefit from early intervention services, such as speech and language therapy, occupational therapy, behavioral therapy, and physical therapy. These therapies can help improve motor skills, communication, social skills, and overall development.
Education support services: People with triple X syndrome are usually of average intelligence but may experience learning difficulties, such as delayed language and reading skills or problems with memory and attention. Educational support, such as individualized education plans (IEPs) and classroom accommodations, can help support their success in school.
Genetic counseling: Families of infants and children diagnosed with trisomy X may benefit from genetic counseling to better understand the disorder and how to support their child best.
Counseling: Some individuals with triple X syndrome may experience behavioral and emotional issues, such as anxiety, depression, and social difficulties. Counseling or psychotherapy can help address these issues and improve emotional well-being.
Hormone therapy: Sometimes, people born with triple X syndrome may experience menstrual irregularities or premature ovarian failure. Hormone therapy, such as hormonal birth control, may be recommended to regulate menstrual cycles.
Regular checkups with a healthcare provider are essential for infants and children with triple X syndrome. Along with parents, a healthcare provider can monitor a child's development for developmental and neuropsychological delays or health problems that may occur.
What Is the Prognosis?Most people with triple X syndrome lead full, healthy lives. They attend school, have careers, parent children, and live as long as their peers who do not have the disorder. Ongoing medical care and support from healthcare professionals ensure those with the condition get the appropriate care and support for any developmental, physical, or cognitive symptoms.
Coping With Triple X SyndromeGetting regular checkups to identify and manage any health, behavioral, or developmental issues that may arise is an important part of living with triple X syndrome. If you have a child with triple X syndrome, early intervention services can help address any developmental delays or social and emotional challenges your child experiences.
Along with support from family members, friends, and professional therapists, many people affected by triple X syndrome find value in joining support groups. In this way, they can connect with others with similar challenges and experience a sense of community.
SummaryTriple X syndrome is a genetic condition that occurs when females are born with three X chromosomes rather than two. While many people with the disorder have no symptoms, it can cause developmental, language, and social delays. Physical characteristics such as flat feet, low muscle tone, wide-spaced eyes, and tall stature are common.
Diagnosis can be made during pregnancy through routine prenatal screening tests or a blood test at any point in a female's life. Treatment options vary depending on the symptoms but may include early intervention services (e.G., speech therapy, occupational therapy), education support, and counseling. With the proper support, most women and girls with triple X syndrome can live healthy, fulfilling lives.
Triple X Syndrome Management Market To Expand At A 6% Value CAGR By 2033FMI Project
The global Triple X Syndrome Management Market is projected to grow at a healthy CAGR of 6% from 2023 to 2033. The market is slated to amass a revenue of US$ 268.63 million by 2033 as opposed to US$ 150 million in 2023.
Research initiatives and other projects from several organizations have significantly benefitted the triple X syndrome management market. In the recent past, NORD and MedicAlert collaboratively initiated a project that offers care for rare disease patients in emergency cases. Initiatives like this are also expected to have a positive influence on the prospects of the triple X syndrome management market over the observation period.
Increasing research efforts by organizations that are empowered with advanced tools and the knowledge of specialists from a wide range of clinical disciplines have resulted in considerable progress in understanding triple x-related illnesses and treatments. In addition, the emergence of an easier scoring system that helps select individuals for triple x syndrome testing will likely bolster the growth of the market.
Get a PDF Sample with the Latest Market Insights @ https://www.Futuremarketinsights.Com/reports/sample/rep-gb-16480
It is further observed that early detection and intervention are vital to market growth. Early detection ensures that patients start treatment right away which bodes well for the expansion of the triple x syndrome management market. Additional guidance can also be provided for a higher standard of living once the condition has been detected.
After detection of the triple x syndrome, children and adults, alike, can opt for psychological counseling for assistance with the resolution of stress and social adaptation. Further, support networks for guardians and caretakers are also beneficial for the patients and their families. For instance, organizations like Counselling and Psychological Services (CPS) and Undergraduate Student Government (USG) are attempting to enhance mental health resources on campus and focus on improving student well-being.
Thus, progressive strategies and initiatives in psychological counseling will drive the growth of the triple x syndrome management market. Though it is estimated that the market will undergo steady growth, it is not without its share of restrictions. A dearth of skilled professionals, high costs associated with treatment methods, and an escalation in the same costs with the installment of novel and sophisticated processes to speed up the recovery are certain factors that will pose a challenge to the growth of the triple x syndrome management market.
Are you looking for customized information related to the latest trends, drivers, and challenges? Speak to Our Analyst @ https://www.Futuremarketinsights.Com/ask-question/rep-gb-16480
Key Takeaways:
Competitive Landscape
Eurofins LifeCodexx GmbH, Illumina Inc., PerkinElmer Inc., and Natera Inc., among others, are a few of the prominent players in the triple X syndrome management market profiled in the full version of the report.
In a competitive environment, several start-ups are coming up with innovative products. For instance, Umbo, an Australian start-up, offers an online platform for speech pathology and occupational therapy. Leading market players are focusing on product innovation and development. These businesses are releasing novel products into the market to retain a competitive edge. For example, Eurofins LifeCodexx GmbH creates specific diagnostics and non-invasive prenatal tests to gain an advantage in the international space.
Triple X Syndrome Treatment, also known as Trisomy X or 47,XXX, is a genetic condition that affects females, where they have an extra X chromosome. This can lead to a range of physical, cognitive, and behavioral symptoms, although many individuals with Triple X syndrome may not experience any significant effects.
Click here today to buy your full report @ https://www.Futuremarketinsights.Com/checkout/16480
Key Segments Profiled in the Triple X Syndrome Management Market Industry Survey
By Treatment:
By End-Users:
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware – 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.ComBrowse All Reports: https://www.Futuremarketinsights.Com/reportsLinkedInTwitterBlogs
Trisomy 21 Causes Down Syndrome
One could argue that the presence of extra copies of chromosome 21 in DS patients is only a correlation between an abnormality and the disease. However, scientists have developed trisomic mouse models that display symptoms of human DS, providing strong evidence that extra copies of chromosome 21 are, indeed, responsible for DS. It is possible to construct mouse models of DS because mouse chromosomes contain several regions that are syntenic with regions on human chromosome 21. (Syntenic regions are chromosomal regions in two different species that contain the same linear order of genes.) With mapping of the human and mouse genomes now complete, researchers can identify syntenic regions in mouse and human chromosomes with great precision.
As shown in Figure 4, regions on the arms of mouse chromosomes 10 (MMU10), 16 (MMU16), and 17 (MMU17) are syntenic with regions on the long q arm of human chromosome 21. Using some genetic tricks, scientists have induced translocations involving these mouse chromosomes, producing mice that are trisomic for regions suspected to play a role in DS. (Note that these are not perfect models, because the trisomic regions contain many mouse genes in addition to those that are syntenic to human chromosome 21 genes.) These experiments have shown that genes from MMU16 are probably most important in DS, because mice carrying translocations from MMU16 display symptoms more like human DS than mice carrying translocations of MMU10 or MMU17.
Additional experiments have tried to identify particularly important genes within this region by transferring smaller segments of the interval on MMU16. For example, the three mouse models depicted on the right in Figure 4 carry different portions of MMU16, and all display some symptoms of DS. Of the three, the most faithful model of DS is the Ts65Dn mouse, which carries 132 genes that are syntenic with human chromosome 21. This particular mouse demonstrates many of the symptoms of human DS, including altered facial characteristics, memory and learning problems, and age-related changes in the forebrain.
These results are both daunting and promising. On one hand, they suggest that there will be no magic bullet for treating DS, because large numbers of genes are most likely involved in the condition. On the other hand, the results suggest that mouse models will be useful in developing treatments for the many DS patients around the world.
Figure 4: Regions of synteny between human chromosome 21 (HSA21) and mouse chromosomes (MMUs) 16, 17, and 10.
There are three partial trisomy mouse models of human trisomy 21, all trisomic for a portion of MMU 16. The gene content of these partial trisomies is shown on the right.
Comments
Post a Comment